Maintenance Therapy In Locally Advanced Stage III NSCLC - Durvalumab

Debate: Systemic Therapy Sequencing In Early Stage Resectable Lung Cancer Neo Adjuvant Vs Adjuvant

Debate: Systemic Therapy Sequencing In Early Stage Resectable Lung Cancer Neo Adjuvant Vs Adjuvant

Case For VIVA - NSCLC-Locally Advanced 15 Min - History/Physical Examination 15 Min- Investigations 30 min- Selection of therapy ( RT versus Sx, NACT versus ACT, Role IO)

Osimertinib Or Decotinib As First Line Therapy In EGFR Mutated Lung Cancer

First Line- TKI + Something In EGFR Mutated Lung Cancer

Mechanism Of Resistance To Osimeritinib In EGFR Mutated Lung Cancer

Post Osimeritinib Options In EGFR Mutated Lung Cancer

Interpretation Of ALK

Selection Of 1st Line Therapy -1st Or 2nd Generation ALK Inhibitors In ALK Rearranged NSCLC

Molecular Resistance Mechanism Of ALK Inhibitors

Selection Of Agent Post 2nd And 3rd Generation ALK Inhibitors Resistance

IO Combinations In First Line NSCLC _ Exploring New Treatment Avenues

Case Base VIVA- Driver Mutated NSCLC

Maintenance Therapy In Locally Advanced Stage III NSCLC - Durvalumab

Debate: Systemic Therapy Sequencing In Early Stage Resectable Lung Cancer Neo Adjuvant Vs Adjuvant

Debate: Systemic Therapy Sequencing In Early Stage Resectable Lung Cancer Neo Adjuvant Vs Adjuvant

Osimertinib Or Decotinib As First Line Therapy In EGFR Mutated Lung Cancer

First Line- TKI + Something In EGFR Mutated Lung Cancer

Mechanism Of Resistance To Osimeritinib In EGFR Mutated Lung Cancer

Post Osimeritinib Options In EGFR Mutated Lung Cancer

Selection Of 1st Line Therapy -1st Or 2nd Generation ALK Inhibitors In ALK Rearranged NSCLC

Molecular Resistance Mechanism Of ALK Inhibitors

Selection Of Agent Post 2nd And 3rd Generation ALK Inhibitors Resistance

IO Combinations In First Line NSCLC _ Exploring New Treatment Avenues